Could LYMPRO be part of this? Pfizer and Roche
Post# of 30070
Posted On: 09/02/2014 8:29:00 AM
Could LYMPRO be part of this?
Pfizer and Roche Join ADDPLAN DF Consortium
New members join Novartis, Janssen, and Eli Lilly to develop adaptive design and execution methodologies for improved decision-making in exploratory studies
Dublin, Ireland August 1, 2014 – ICON plc (NASDAQ: ICLR), today announced that Pfizer and Roche have joined the ADDPLAN® DF Consortium. The consortium was founded in 2013 by Novartis Pharma AG, Janssen Pharmaceuticals Inc., Eli Lilly, and Aptiv Solutions, which is an ICON plc company leading the design and implementation of adaptive trials. The goal of the ADDPLAN DF Consortium is to develop methodologies and execution technologies that improve dose-selection, which remains a major barrier to resolving high failure rates in Phase III trials. Both Pfizer’s and Roche’s decision to join the Consortium comes as more companies recognise the value of adaptive design in improving decision making in exploratory development.
The ADDPLAN DF Consortium statisticians are currently collaborating to expand the utility of the Multiple Comparison Procedure and Modeling (MCP-Mod) approach, specifically by developing robust methodology for incorporating adaptive functionality. The current MCP-Mod procedure enables Proof of Concept (PoC) and dose selection to be established in a single trial. The ability to go beyond the current approach and include interim decision making into the MCP-Mod procedure will build in additional efficiency and flexibility.
“The membership of Pfizer and Roche, long time proponents of adaptive design, significantly strengthens the Consortium’s ability to develop validated, regulatory-compliant software for the design and execution of adaptive trials,” says Reinhard Eisebitt, Executive Vice President and Head of ICON’s Adaptive Trial Innovation Center. “Since its formation last year, the ADDPLAN DF Consortium has provided invaluable insight to further enhance the software, including the addition of adaptive dose-escalation functionality and more simulation metrics, improved plotting functionalities for simulation results, and an extension to documentation.”
ICON will hold an ADDPLAN User Group meeting on August 4, 2014 from 4:30 to 6:30 PM, at the Seaport Hotel, Boston, MA. Jose Pinheiro, Ph.D., Senior Director, Quantitative Decision Strategies at Janssen, and co-developer of MCP-Mod, will give a talk on the basics of MCP-Mod; David Ohlssen, Ph.D., Senior Expert Methodologist at Novartis, will present a case study on the use of adaptive MCP-Mod for a multiple sclerosis trial; and Tobias Mielke, Ph.D., Statistical Consultant at Aptiv Solutions, will speak about the use and development of ADDPLAN DF. An open Q&A will take place following the presentations. Registration is limited to 20 attendees and can be completed by emailing inquiry@aptivsolutions.com
Pfizer and Roche Join ADDPLAN DF Consortium
New members join Novartis, Janssen, and Eli Lilly to develop adaptive design and execution methodologies for improved decision-making in exploratory studies
Dublin, Ireland August 1, 2014 – ICON plc (NASDAQ: ICLR), today announced that Pfizer and Roche have joined the ADDPLAN® DF Consortium. The consortium was founded in 2013 by Novartis Pharma AG, Janssen Pharmaceuticals Inc., Eli Lilly, and Aptiv Solutions, which is an ICON plc company leading the design and implementation of adaptive trials. The goal of the ADDPLAN DF Consortium is to develop methodologies and execution technologies that improve dose-selection, which remains a major barrier to resolving high failure rates in Phase III trials. Both Pfizer’s and Roche’s decision to join the Consortium comes as more companies recognise the value of adaptive design in improving decision making in exploratory development.
The ADDPLAN DF Consortium statisticians are currently collaborating to expand the utility of the Multiple Comparison Procedure and Modeling (MCP-Mod) approach, specifically by developing robust methodology for incorporating adaptive functionality. The current MCP-Mod procedure enables Proof of Concept (PoC) and dose selection to be established in a single trial. The ability to go beyond the current approach and include interim decision making into the MCP-Mod procedure will build in additional efficiency and flexibility.
“The membership of Pfizer and Roche, long time proponents of adaptive design, significantly strengthens the Consortium’s ability to develop validated, regulatory-compliant software for the design and execution of adaptive trials,” says Reinhard Eisebitt, Executive Vice President and Head of ICON’s Adaptive Trial Innovation Center. “Since its formation last year, the ADDPLAN DF Consortium has provided invaluable insight to further enhance the software, including the addition of adaptive dose-escalation functionality and more simulation metrics, improved plotting functionalities for simulation results, and an extension to documentation.”
ICON will hold an ADDPLAN User Group meeting on August 4, 2014 from 4:30 to 6:30 PM, at the Seaport Hotel, Boston, MA. Jose Pinheiro, Ph.D., Senior Director, Quantitative Decision Strategies at Janssen, and co-developer of MCP-Mod, will give a talk on the basics of MCP-Mod; David Ohlssen, Ph.D., Senior Expert Methodologist at Novartis, will present a case study on the use of adaptive MCP-Mod for a multiple sclerosis trial; and Tobias Mielke, Ph.D., Statistical Consultant at Aptiv Solutions, will speak about the use and development of ADDPLAN DF. An open Q&A will take place following the presentations. Registration is limited to 20 attendees and can be completed by emailing inquiry@aptivsolutions.com
(0)
(0)